Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus HYPAQUE SODIUM 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus HYPAQUE SODIUM 20.
HYPAQUE-M,90% vs HYPAQUE SODIUM 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent